{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:08:56Z","timestamp":1791198536009,"version":"4.1.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/iae.0b013e318214d076","type":"journal-article","created":{"date-parts":[[2011,7,9]],"date-time":"2011-07-09T08:28:42Z","timestamp":1310200122000},"page":"2050-2057","source":"Crossref","is-referenced-by-count":20,"title":["PRESERVATIVE-FREE TRIAMCINOLONE ACETONIDE INJECTABLE SUSPENSION VERSUS \u201cTRADITIONAL\u201d TRIAMCINOLONE PREPARATIONS"],"prefix":"10.1097","volume":"31","author":[{"given":"Martin S","family":"Spitzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Mlynczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Schultheiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Rinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efdal","family":"Yoeruek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Petermeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Januschowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Szurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210616","first-page":"171","article-title":"Treatment of intraocular proliferations with intravitreal steroids.","volume":"77","author":"Machemer","year":"1979","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R2-13-20210616","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0002-9394(14)75196-7","article-title":"Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide.","volume":"90","author":"Tano","year":"1980","journal-title":"Am J Ophthalmol"},{"key":"R3-13-20210616","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0161-6420(00)00658-8","article-title":"Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study.","volume":"108","author":"Antcliff","year":"2001","journal-title":"Ophthalmology"},{"key":"R4-13-20210616","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/S0161-6420(02)00975-2","article-title":"Intravitreal triamcinolone for refractory diabetic macular edema.","volume":"109","author":"Martidis","year":"2002","journal-title":"Ophthalmology"},{"key":"R5-13-20210616","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/archopht.121.1.57","article-title":"Intravitreal injection of triamcinolone for diffuse diabetic macular edema.","volume":"121","author":"Jonas","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R6-13-20210616","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00006982-200003000-00004","article-title":"Intravitreal triamcinolone acetonide in exudative age-related macular degeneration.","volume":"20","author":"Danis","year":"2000","journal-title":"Retina"},{"key":"R7-13-20210616","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/sj.eye.6701438","article-title":"Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study.","volume":"19","author":"Jonas","year":"2005","journal-title":"Eye"},{"key":"R8-13-20210616","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0002-9394(00)00882-5","article-title":"Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy.","volume":"131","author":"Jonas","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"R9-13-20210616","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1136\/bjo.84.9.1064","article-title":"Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy.","volume":"84","author":"Jonas","year":"2000","journal-title":"Br J Ophthalmol"},{"key":"R10-13-20210616","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0008-4182(05)80052-3","article-title":"Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy.","volume":"40","author":"Munir","year":"2005","journal-title":"Can J Ophthalmol"},{"key":"R11-13-20210616","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/00006982-200005000-00024","article-title":"Triamcinolone acetonide as an aid to visualization of the vitreous and the posterior hyaloids during pars plana vitrectomy.","volume":"20","author":"Peyman","year":"2000","journal-title":"Retina"},{"key":"R12-13-20210616","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0886-3350(03)00016-6","article-title":"Visualizing vitreous using Kenalog suspension.","volume":"29","author":"Burk","year":"2003","journal-title":"J Cataract Refract Surg"},{"key":"R13-13-20210616","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ajo.2004.05.033","article-title":"Intracameral triamcinolone helps to visualize and remove the vitreous body in anterior chamber in cataract surgery.","volume":"138","author":"Yamakiri","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R14-13-20210616","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ophtha.2003.05.034","article-title":"Residual vitreous cortex after surgical posterior vitreous separation visualized by intravitreous triamcinolone acetonide.","volume":"111","author":"Sonoda","year":"2004","journal-title":"Ophthalmology"},{"key":"R15-13-20210616","first-page":"56","article-title":"Triamcinolone acetonide facilitates removal of the epiretinal membrane and separation of the residual vitreous cortex in highly myopic eyes with retinal detachment due to a macular hole.","volume":"32","author":"Yamamoto","year":"2004","journal-title":"Ophthalmologica"},{"key":"R16-13-20210616","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.1167\/iovs.03-0490","article-title":"The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone.","volume":"44","author":"Yeung","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R17-13-20210616","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.exer.2006.02.012","article-title":"Differential toxic effect of dissolved triamcinolone and its crystalline deposits on cultured human retinal pigment epithelium (ARPE19) cells.","volume":"83","author":"Szurman","year":"2006","journal-title":"Exp Eye Res"},{"key":"R18-13-20210616","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.exer.2007.03.003","article-title":"Different biocompatibility of crystalline triamcinolone deposits on retinal cells in vitro and in vivo.","volume":"85","author":"Szurman","year":"2007","journal-title":"Exp Eye Res"},{"key":"R19-13-20210616","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/IAE.0b013e318188c6e2","article-title":"Clinical evaluation of the safety and efficacy of preservative-free triamcinolone (Triesence [triamcinolone acetonide injectable suspension] 40 mg\/ml) for visualization during pars plana vitrectomy.","volume":"29","author":"Dyer","year":"2009","journal-title":"Retina"},{"key":"R20-13-20210616","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3928\/1542-8877-20040701-18","article-title":"A simple and rapid method for purification of triamcinolone acetonide suspension for intravitreal injection.","volume":"35","author":"Hernaez-Ortega","year":"2005","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"R21-13-20210616","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3233\/BIR-1992-295-612","article-title":"Rheology of the vitreous body. Part I: Viscoelasticity of human vitreous.","volume":"29","author":"Lee","year":"1992","journal-title":"Biorheology"},{"key":"R22-13-20210616","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3233\/BIR-1994-31403","article-title":"Rheology of the vitreous body: Part 2. Viscoelasticity of bovine and porcine vitreous.","volume":"31","author":"Lee","year":"1994","journal-title":"Biorheology"},{"key":"R23-13-20210616","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00417-008-0980-7","article-title":"Physiology of vitreous surgery.","volume":"247","author":"Stefansson","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R24-13-20210616","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/00006982-200310000-00014","article-title":"Infectious and presumed non-infectious endophthalmitis after intravitreal triamcinolone acetonide injection.","volume":"23","author":"Nelson","year":"2003","journal-title":"Retina"},{"key":"R25-13-20210616","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1167\/iovs.06-1146","article-title":"Cytotoxicity of triamcinolone acetonide on human retinal pigment epithelial cells.","volume":"48","author":"Chang","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R26-13-20210616","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00417-006-0436-x","article-title":"Influence of different purification techniques on triamcinolone yield and particle size spectrum.","volume":"245","author":"Szurman","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R27-13-20210616","first-page":"45","article-title":"Intraocular Steroids in the Office. New formulations offer preservative-free triamcinolone without relying on compounding pharmacies.","volume":"1","author":"Haller","year":"2009","journal-title":"Retin Phys"},{"key":"R28-13-20210616","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-3659(99)00230-8","article-title":"Drug solubilization in lung surfactant.","volume":"65","author":"Wiedmann","year":"2000","journal-title":"J Control Release"},{"key":"R29-13-20210616","first-page":"847","article-title":"Accidental intraocular injection of depot corticosteroids.","volume":"78","author":"Schlaegel","year":"1978","journal-title":"Trans Am Acad Ophthalmol Otolaryngol"},{"key":"R30-13-20210616","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/01.iae.0000244255.22406.2f","article-title":"Evaluation of the toxicity of subretinal triamcinolone acetonide in rabbits.","volume":"26","author":"Kozak","year":"2006","journal-title":"Retina"},{"key":"R31-13-20210616","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/IAE.0b013e31819e390a","article-title":"Triamcinolone acetonide preparations: impact of crystal size on in vitro behavior.","volume":"29","author":"Moshfeghi","year":"2009","journal-title":"Retina"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006982-201111000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T19:32:02Z","timestamp":1786044722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006982-201111000-00013"}},"subtitle":["Impact of Aggregate Size on Retinal Biocompatibility"],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0b013e318214d076","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}